Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06500494

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

Sponsor: Pierre Fabre Medicament

View on ClinicalTrials.gov

Summary

This study looks at how well oral vinorelbine works in treating advanced breast cancer. It looks at women who have already had this treatment or are currently having it.

Official title: Advanced Breast Cancer Patients Treated With Oral Vinorelbine: a Prospective and Retrospective, Observational Study - VINOREAL

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

368

Start Date

2024-09-10

Completion Date

2028-02

Last Updated

2025-07-24

Healthy Volunteers

No

Interventions

DRUG

Vinorelbine Tartrate Oral

The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.

Locations (3)

Centre Hospitalo-Universitaire Mustapha, Hopital Mustapha, Place du 1er Mai 1945, Sidi M'Hamed

Algiers, Algeria

Tianjing Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Azienda Ospedaliera San Gerardo U.O. Oncologia Medica

Monza, Italy